Summit Therapeutics Inc. 8K

Summit Therapeutics’ 8-K reports Q2 2026 financial results, strong cash resources, major clinical milestones and collaborations for ivonescimab, and the sale of its ridinilazole asset.

Summit Therapeutics Inc. filed a Form 8-K to furnish a press release reporting its financial results and operational progress for the quarter and six months ended June 30, 2026, highlighting continued clinical momentum for its lead bispecific antibody ivonescimab (SMT112), including updated overall survival data from the global Phase III HARMONi trial in EGFR-mutated NSCLC, positive Phase III HARMONi-6 overall survival results from China demonstrating superiority over an anti-PD-1 regimen, completion of enrollment in both cohorts of the global Phase III HARMONi-3 NSCLC study, ongoing global Phase III programs (HARMONi-7, HARMONi-GI3) and multiple external collaborations, the divestiture of its antibiotic asset ridinilazole to Biossil, and detailed second-quarter 2026 financial metrics showing a GAAP net loss of $215.7 million, non-GAAP net loss of $147.0 million, and a robust cash and investments balance of $690.7 million, supported by $230.8 million raised via its ATM facility during the quarter and an additional $68.4 million raised subsequent to quarter-end.

Filing Facts

CIK

1599298

Ticker

SMMT

Form

8K

Source Type

fda

Accession

0001599298-26-000067

Alert Tier

6